Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Vaxcyte, Inc. (PCVX)
|
Add to portfolio |
|
|
|
| Price: |
$25.38
| | Metrics |
| OS: |
93.8
|
M
| |
-18
|
% ROE
|
| Market cap: |
$2.38
|
B
| |
|
|
|
Net cash:
|
$531
|
M
| |
$5.66
|
per share
|
|
EV:
|
$1.85
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
($2.80)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 169.5 | 0.0 | 78.4 | 0.0 | 73.6 | 0.0 | 0.0 |
| Revenue growth | | 116.1% | | 6.6% | | | | |
| Cost of goods sold | 0.0 | 169.5 | 0.0 | 103.7 | 0.0 | 89.6 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | -25.3 | 0.0 | -16.0 | 0.0 | 0.0 |
| Gross margin | | 0.0% | | -32.2% | | -21.8% | | |
| Selling, general and administrative | 232.3 | | 103.7 | | 89.6 | | 54.2 | |
| Research and development | | | | | | | | 30.1 |
| General and administrative | | 39.8 | | 25.3 | | 16.0 | | 5.4 |
| EBIT | 0.0 | -232.3 | 0.0 | -103.7 | 0.0 | -89.6 | -50.3 | -35.5 |
| EBIT margin | | -137.1% | | -132.2% | | -121.8% | | |
| Pre-tax income | -223.5 | 0.0 | -100.1 | 0.0 | -89.2 | 0.0 | -50.3 | -29.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 0.0% | | 0.0% | | 0.0% | 0.0% |
| Net income | -223.5 | 0.0 | -100.1 | 0.0 | -89.2 | 0.0 | -50.3 | -29.5 |
| Net margin | | 0.0% | | 0.0% | | 0.0% | | |
| |
| Diluted EPS | ($3.44) | $0.00 | ($1.93) | $0.00 | ($3.02) | $0.00 | ($13.25) | ($8.12) |
| Shares outstanding (diluted) | 64.9 | 64,878.0 | 51.9 | 51.9 | 29.5 | 29,545.8 | 3.8 | 3.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|